Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase 2 Study in Adults Sensitized to Cat

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Antigen Laboratories, Inc.
ClinicalTrials.gov Identifier:
NCT00689299
First received: May 30, 2008
Last updated: April 14, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to identify an effective dose of allergen-specific immunotherapy for cat hair (Felis domesticus) administered by the oral/sublingual route.


Condition Intervention Phase
Allergy
Biological: Standardized Allergenic Extract, Cat Hair
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (Felis Domesticus)

Resource links provided by NLM:


Further study details as provided by Antigen Laboratories, Inc.:

Primary Outcome Measures:
  • Scores on a Scale (Average of Total Symptom Scores) [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]

    Sum of individual symptoms scores, 7 items, 21 points maximum

    Total Symptom Scores during environmental chamber exposures at week 20. The Total Symptom Score was defined as the sum of the scores from the following seven symptoms rated 0-3 (0=absent, 1=mild, 2= moderate, 3=severe): runny nose, sneezing, itching nose, nasal congestion, watery eyes, itchy eyes, and itchy ears/palate/throat.

    Total Symptom score could range from 0-21; the lower the score, the more favorable the outcome. Each symptom parameter was graded by the study subject every 10 minutes for up to 60 minutes during the baseline (Day 0) and during the Week 20 environmental chamber exposures.



Enrollment: 167
Study Start Date: October 2008
Study Completion Date: June 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Dose Group C
Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo
Biological: Placebo
Placebo Sublingual Drops
Active Comparator: Dose Group A
Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units
Biological: Standardized Allergenic Extract, Cat Hair
Standardized Cat Hair Allergenic Extract sublingual drops
Other Name: Standardized Cat Hair Allergenic Extract
Active Comparator: Dose Group B
Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units
Biological: Standardized Allergenic Extract, Cat Hair
Standardized Cat Hair Allergenic Extract sublingual drops
Other Name: Standardized Cat Hair Allergenic Extract

Detailed Description:

This was a phase 2, randomized, double-blind, placebo-controlled, parallel groups study conducted in 3 centers in the US (NCT00689299). Study drug was sublingually dosed once daily as 0.15 mL of US standardized cat hair extract dosed either undiluted, as 1:10 dilution, or placebo. Target dose was obtained on Day 3 of dose titration escalating through 1:100 and 1:10 dilutions on Day 1 and Day 2 in the high dose group or placebo and 1:100 dilutions in the low dose group. Treatment duration was 20 weeks. Adult (>18 years) study subjects had positive history for cat allergy without asthma, positive skin test to cat allergen, absence of immunotherapy during the prior 2 years, and absence of other confounding baseline conditions. The primary outcome parameter was average Total Symptom Score (TSS) during a 1-hour cat chamber exposure. TSS is the sum of 7 items rated from 0 - 3 (none to severe) for nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing) and non-nasal symptoms (eye watering, eye itching, and itching palate/ ear/ throat).

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients between ages of 18 and 55 years (inclusive).
  • Written informed consent to participate in the study.
  • Documented allergy to cat hair as demonstrated by a positive epicutaneous skin test (wheal >3 mm) and symptoms of allergic rhinitis during exposure to cats.
  • Female subjects of childbearing potential, defined as not surgically sterile or at least 2 years postmenopausal, must agree to use one of the following forms of contraception from screening through the 4 week follow-up period following the last dose of clinical trial: hormonal begun >30 days prior to screening, barrier, intrauterine device or vasectomized partner (6 months minimum).
  • No clinically significant abnormal findings on physical examination, with the exception of head, ears, eyes, nose, and throat (HEENT) findings consistent with allergic rhinitis, medical history, or clinical laboratory results during screening which would jeopardize the safety of the subject or impact validity of study results.

Exclusion Criteria:

  • Previous allergen immunotherapy (subcutaneous immunotherapy (SCIT), oral immunotherapy, sublingual immunotherapy (SLIT) or recombinant peptide) for cat within 24 months of Screening Visit.
  • History of severe allergic reaction requiring medical intervention.
  • Intolerance of or severe allergic reaction to previous immunotherapy (SCIT, oral immunotherapy, SLIT, or recombinant peptide).
  • Allergy to any of the non-antigen ingredients in the study drug formulation, including, but not limited to: Food, Drug and Cosmetic Act (FD&C) Yellow #5, Red #40 and Blue #1; sodium chloride; sodium bicarbonate; and glycerine.
  • History of asthma requiring daily medication.
  • Subjects receiving anti-IgE monoclonal antibodies.
  • Congenital immune deficiency or acquired immune suppression. Causes of acquired immune suppression may include, but are not limited to, systemic illnesses such as malignancy and infection, the use of medications such as corticosteroids and chemotherapeutic agents, and radiation therapy.
  • History of organ transplant, hematologic malignancy, autoimmune disease, myocardial infarction, or congestive heart failure.
  • History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, psychiatric, or cardiovascular disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • Inability or unwillingness to stop using drugs that may inhibit the wheal-and-flare reaction or rhinitic response prior to the study and for the duration of dosing clinical trial material (CTM), with the exception of protocol-specified rescue medications provided by the study site for use after Study Day 0. This includes, but is not limited to:

    • Decongestants for 3 days prior to Study Day 0
    • H1 antagonists (antihistamines) (oral, nasal or ocular) for 7 days prior to Study Day 0
    • Topical intranasal corticosteroids for 14 days prior to Study Day 0
    • Cromolyn or nedocromil for 14 days prior to Study Day 0
    • Systemic corticosteroids for 28 days prior to Study Day 0
    • Tricyclic antidepressants for 28 days prior to Study Day 0
    • Leukotriene modifiers for 7 days prior to study Day 0
  • Inability or unwillingness to stop using drugs that may inhibit the ability to treat a severe allergic adverse event. This includes, but is not limited to: beta blockers such as atenolol (Tenormin®), metoprolol (Lopressor®, Toprol-XL®) and propranolol (Inderal®, Inderal LA®) for 14 days prior to Study Day 0 and for the duration of the study.
  • Female subjects who are trying to conceive, are pregnant, or are lactating.
  • Positive serum pregnancy test at screening or a positive human chorionic gonadotropin (HCG) urine test on Study Day 0 prior to administration of study drug for women of childbearing potential.
  • Positive blood screen for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HbSAg), or Hepatitis C.
  • Forced Expiratory Volume in 1 second (FEV1) <70% of the predicted value.
  • History of alcohol or drug abuse within the year prior to the Screening Visit, or current evidence of substance dependence or abuse.
  • Participation in a clinical trial or receipt of a non-FDA approved therapy within 30 days prior to the Screening Visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00689299

Locations
United States, California
Allergy & Asthma Medical Group & Research Center
San Diego, California, United States, 92123
United States, Georgia
Allergen Response and Research Center
Marietta, Georgia, United States, 30062
United States, Missouri
Clinical Research Center
St. Louis, Missouri, United States, 63141
Sponsors and Collaborators
Antigen Laboratories, Inc.
Investigators
Principal Investigator: Robert B. Berkowitz, M.D. Allergen Response Research Center
  More Information

No publications provided

Responsible Party: Antigen Laboratories, Inc.
ClinicalTrials.gov Identifier: NCT00689299     History of Changes
Other Study ID Numbers: ALI002-08, ALI002-08
Study First Received: May 30, 2008
Results First Received: May 24, 2011
Last Updated: April 14, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Antigen Laboratories, Inc.:
Sublingual Immunotherapy (SLIT)
Non-seasonal allergic rhinitis
Immunotherapy
Allergic rhinitis
Cat
Perennial allergy
Non-seasonal allergy

ClinicalTrials.gov processed this record on November 24, 2014